Mesenchymal stem cell preparation as well as preparation method and application thereof

Through mesenchymal stem cell preparation, combined with fibroblast growth factor 23, the toxic side effects and long-term consumption problems in the treatment of autoimmune hepatitis are solved, significantly improve the inflammatory status and damage of the liver, promote liver repair, and provide a safer and more Effective treatment options.

CN118948897APending Publication Date: 2024-11-15NANJING UNIV +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411054934.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing treatments for autoimmune hepatitis have strong toxic side effects and long-term consumption problems, and a safer and more effective treatment plan is needed.

Method used

A mesenchymal stem cell preparation, including human umbilical cord mesenchymal stem cells and fibroblast growth factor 23 (FGF23), was developed to prepare the preparation by specific preparation methods for the treatment of autoimmune hepatitis. This preparation reduces liver inflammation and damage by inhibiting the release of inflammatory mediators, regulating immune cell function and promoting tissue repair.

Benefits of technology

In the mouse model of autoimmune hepatitis, the content of ALT, AST and inflammatory cytokines in the serum was significantly reduced, the pro-inflammatory regressed, the content of anti-inflammatory factor IL-10 increased significantly, the cytotoxic T cells decreased, and regulatory T cells increased. , the immune inflammatory microenvironment in the liver is improved, and liver tissue repair is enhanced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948897A_ABST
    Figure CN118948897A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of stem cells, in particular to a mesenchymal stem cell preparation as well as a preparation method and application thereof. The mesenchymal stem cell preparation disclosed by the invention is obtained by mixing human umbilical cord mesenchymal stem cells and a human fibroblast growth factor FGF23. After the mesenchymal stem cell preparation is intravenously injected into an autoimmune hepatitis mouse model, the liver inflammation state and damage of the autoimmune hepatitis mouse can be remarkably improved, liver repair is promoted, and the main manifestation is that the contents of alanine transaminase (ALT), aspartate transaminase (AST) and inflammatory cytokines in serum are remarkably reduced, and the content of the inflammatory cytokines is remarkably reduced. The content of an anti-inflammatory factor (IL-10) for promoting inflammation fading is remarkably increased, the content of cytotoxic T cells (CTL, CD8 + CD3 +) is remarkably reduced, and the content of regulatory T cells (Treg, CD4 + CD25 +) is remarkably increased.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of stem cells, and in particular to a mesenchymal stem cell preparation and a preparation method thereof, and application thereof in autoimmune hepatitis. Background Art

[0002] Autoimmune hepatitis (AIH) is a chronic autoimmune disease characterized by liver inflammation. Its etiology is not fully understood, but it is generally believed to be caused by a combination of genetic, environmental, and immune system disorders. In autoimmune hepatitis, the immune system mistakenly attacks healthy liver tissue, leading to liver inflammation, fibrosis, and impaired liver function. If autoimmune hepatitis is not treated in time, it may lead to serious consequences such as cirrhosis, liver failure, and even liver cancer, which seriously affects the patient's quality of life and survival. Therefore, early diagnosis and treatment of autoimmune hepatitis are crucial. Currently, commonly used treatment strategies include immunosuppressants (such as glucocorticoids and azathioprine), immunomodulators (such as cyclosporine and methotrexate), and antiviral drugs. These treatments aim to suppress abnormal responses of the immune system, reduce liver inflammation, delay disease progression, and maintain stable liver function. These methods can achieve certain therapeutic effects, but they still have obvious defects, such as strong toxic side effects and the need for long-term use. Therefore, it is necessary to update the technical system and build a more effective and safer treatment plan for autoimmune hepatitis.

[0003] Mesenchymal stem cells (MSCs) are a type of multipotent stem cells with a wide range of cell biological properties and application potential. MSCs are most commonly isolated and cultured from bone marrow, adipose tissue, and other tissues, and have properties such as self-renewal, multidirectional differentiation, and immunomodulation. Mesenchymal stem cells are widely used in clinical practice and research. They can differentiate into many different types of cells, such as osteoblasts, chondrocytes, and adipocytes, and therefore have important value in the fields of tissue engineering and regenerative medicine. In addition, MSCs also exhibit significant immunomodulatory and anti-inflammatory effects and are considered to have potential advantages in the treatment of inflammatory diseases. In terms of inflammation control, mesenchymal stem cells can reduce inflammatory responses, relieve symptoms of inflammatory diseases, and promote tissue repair and regeneration by inhibiting the release of inflammatory mediators, regulating immune cell function, and promoting tissue repair. This makes MSCs a potential therapeutic approach for the treatment of inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and autoimmune diseases.

[0004] Fibroblast Growth Factor (FGF) is an important family of growth factors that plays an important role in regulating biological processes such as cell proliferation, differentiation and survival. In recent years, studies have shown that FGF has an important influence on stem cell function and tissue inflammation repair. FGF can promote the proliferation and differentiation of stem cells, regulate their self-renewal and multidirectional differentiation capabilities, and thus affect the function of stem cells. In addition, FGF can also regulate the interaction between stem cells and surrounding tissues, promoting tissue regeneration and repair processes. In terms of tissue inflammation repair, FGF has anti-inflammatory and healing effects. FGF can regulate inflammatory responses, inhibit the release of inflammatory mediators, reduce tissue inflammatory responses, and promote the repair and regeneration of damaged tissues. This makes FGF have potential clinical application prospects in the treatment of inflammatory diseases and the promotion of tissue repair.

[0005] There is evidence that MSCs treated with FGF can change their secretion profile, enhance the inflammation control and tissue repair functions of MSCs, identify specific FGF family members, and apply them to the development of MSC preparations, which will help to build a new treatment system for intervening in autoimmune hepatitis. Summary of the invention

[0006] Purpose of the invention: The technical problem to be solved by the present invention is to provide a mesenchymal stem cell preparation and its preparation method and application in view of the deficiencies in the prior art.

[0007] In order to solve the above technical problems, the present invention discloses a mesenchymal stem cell preparation and its preparation method and application. The specific technical scheme is as follows:

[0008] A mesenchymal stem cell preparation comprises human umbilical cord mesenchymal stem cells and fibroblast growth factor 23.

[0009] Wherein, the fibroblast growth factor 23 is human fibroblast growth factor 23. The fibroblast growth factor (FGF) 23 can enhance the anti-inflammatory function of MSC.

[0010] Wherein, the mesenchymal stem cell preparation further comprises physiological saline, and the concentration of human umbilical cord mesenchymal stem cells in the mesenchymal stem cell preparation is 10 6 -10 7 cells / mL, the concentration of fibroblast growth factor 23 is 100-1000 ng / mL, preferably, the concentration of fibroblast growth factor 23 is 1000 ng / mL.

[0011] In a second aspect, the present invention provides a method for preparing the mesenchymal stem cell preparation according to the first aspect, comprising the following steps:

[0012] (1) placing human umbilical cord mesenchymal stem cells in a culture medium, culturing until the cell abundance is 70%-80%, adding fibroblast growth factor 23, calcitriol and saikosaponin, continuing to culture for 18-48 hours, and adding trypsin for digestion; preferably, the culture temperature is 37° C., and the culture is continued for 48 hours after adding fibroblast growth factor 23, calcitriol and saikosaponin.

[0013] (2) washing and resuspending the human umbilical cord mesenchymal stem cells obtained in step (1), and collecting them through a cell sieve to obtain a single cell suspension;

[0014] (3) Adding fibroblast growth factor 23 to the single cell suspension to obtain a mesenchymal stem cell preparation.

[0015] Wherein, in step (1), the human umbilical cord mesenchymal stem cells are extracted by the following method: adding CDH digestive enzyme to Wharton's jelly for digestion, centrifuging to remove the supernatant, resuspending in DMEM / F12 medium containing fetal bovine serum, and culturing until the cell abundance is 70%-80% to isolate human umbilical cord mesenchymal stem cells. Preferably, the human umbilical cord mesenchymal stem cells are isolated when the cell abundance is 80% at 37°C. Further preferably, the Wharton's jelly is extracted from human umbilical cord tissue.

[0016] Wherein, the CDH digestive enzyme comprises type II collagenase, neutral protease and hyaluronidase; the CDH digestive enzyme is added in the form of CDH digestive enzyme solution; the solvent of the CDH digestive enzyme solution is DMEM / F12 culture medium, wherein the concentration of type II collagenase is 250U / mL, the concentration of neutral protease is 100U / mL, and the concentration of hyaluronidase is 10U / mL; the volume ratio of the CDH digestive enzyme solution to the Wharton's jelly is 1-5:1, preferably 1:1.

[0017] Wherein, in step (1), the fibroblast growth factor 23 is added at a concentration of 100-500 ng / mL; the calcitriol is added at a concentration of 1-5 μM; and the saikosaponin is added at a concentration of 1-10 μM. Preferably, the fibroblast growth factor 23 is human fibroblast growth factor 23, and the added concentration is 500 ng / mL; the calcitriol is added at a concentration of 5 μM; and the saikosaponin is saikosaponin A, and the added concentration is 10 μM. Further preferably, the amount of pancreatin used is 10 μM per 10 6 2 mL of 0.25% g / mL pancreatin is added to the cells; the digestion temperature is 37° C. and the digestion time is 2-5 min. Preferably, the culture medium is DMEM / F12 medium containing 10% fetal bovine serum.

[0018] Wherein, in step (2), physiological saline is used for washing and resuspending; and the cell sieve is a 100 μm cell sieve.

[0019] Preferably, in step (3), the fibroblast growth factor 23 is human fibroblast growth factor 23, and the added concentration is 100-1000 ng / mL, preferably 1000 ng / mL.

[0020] In a third aspect, the present invention provides use of the mesenchymal stem cell preparation described in the first aspect in the preparation of a drug for treating autoimmune hepatitis.

[0021] Preferably, the mesenchymal stem cell preparation is an intravenous injection preparation.

[0022] The mesenchymal stem cell preparation prepared by the present invention is directly injected into the tail vein of an autoimmune hepatitis mouse model, which can significantly improve the liver inflammation state and damage of the autoimmune hepatitis mouse and promote liver repair.

[0023] Beneficial effects:

[0024] The present invention analyzes the expression of UC-MSC's own FGF protein under inflammatory stimulation and finds that FGF23 has a potential function in UC-MSC's own anti-inflammatory regulation. Human umbilical cord mesenchymal stem cells UC-MSC and FGF23 are mixed to obtain a mesenchymal stem cell preparation. After intravenous injection of the mesenchymal stem cell preparation in an autoimmune hepatitis mouse model, the liver inflammation state and damage of the autoimmune hepatitis mouse can be significantly improved, and liver repair can be promoted, specifically: the content of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and inflammatory cytokines in serum is significantly reduced, the content of anti-inflammatory factors (IL-10) that promote inflammation resolution is significantly increased, the content of cytotoxic T cells (CTL, CD8+CD3+) is significantly reduced, and the content of regulatory T cells (Treg, CD4+CD25+) is significantly increased, the immune inflammatory microenvironment in the liver is improved, and the repair process in the liver tissue is enhanced. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.

[0026] Figure 1 The figure is the expression of FGF protein of MSC itself; among them, MSC-Con is MSC without inflammatory stimulation, and MSC-TNFa is MSC with inflammatory stimulation.

[0027] Figure 2 Figure 2 shows the expression of inflammatory genes in macrophages.

[0028] Figure 3 Mouse liver tissue was sectioned for H&E case analysis.

[0029] Figure 4 It is the level of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum.

[0030] Figure 5 It is the content of inflammatory cytokines and anti-inflammatory factors (IL-10) in serum.

[0031] Figure 6 Flow cytometry was used to analyze the infiltration ratio of cytotoxic T cells (CD3+CD8+) and regulatory T cells Treg (CD3+CD25+) in the liver. DETAILED DESCRIPTION

[0032] The principles and features of the present invention are described below in conjunction with examples, which are only used to explain the present invention and are not used to limit the scope of the present invention. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0033] Example 1 Extraction of human umbilical cord-derived mesenchymal stem cells (UC-MSC)

[0034] (1) Under sterile conditions, 10-30 cm of human umbilical cord tissue was placed in sterile saline (containing 100 U / mL penicillin and 0.1 mg / mL streptomycin), placed on ice, and digested and separated within 12 hours of collection.

[0035] (2) In a clean bench, rinse the umbilical cord twice with sterile PBS (pH = 7.5) to remove residual blood.

[0036] (3) Place the umbilical cord in MEM-F12 culture medium, peel off the amniotic membrane, two arteries and one vein of the umbilical cord tissue, and cut the remaining umbilical cord tissue (Wharton's jelly) into 1-3 mm thick pieces with scissors. 3 Fragments left and right.

[0037] (4) Prepare CDH digestive enzymes (including type II collagenase, neutral protease and hyaluronidase), dissolve in DMEM / F12 culture medium at 37°C, where the concentration of type II collagenase is 250 U / mL, the concentration of neutral protease is 100 U / mL, and the concentration of hyaluronidase is 10 U / mL, and filter through a 0.22 μm filter for sterilization and set aside.

[0038] (5) The chopped tissue obtained in step (3) was mixed with CDH digestion enzyme solution in a volume ratio of 1:1 in a 50 mL centrifuge tube, placed in a 37°C shaker, shaken at 200 rpm, and digested for 3 h.

[0039] (6) Centrifuge the digested tissue fluid at 4°C, 300g for 5 min, and discard the supernatant. Resuspend the precipitate in 50 mL of fresh DMEM / F12 medium (containing 100 U / mL penicillin and 0.1 mg / mL streptomycin) with PBS (pH = 7.5), centrifuge at 4°C, 300g for 5 min, and discard the supernatant. Wash twice with PBS (pH = 7.5).

[0040] (7) The precipitate was resuspended in DMEM / F12 medium (containing 100 U / mL penicillin and 0.1 mg / mL streptomycin) containing 15% fetal bovine serum, and plated into a (T-25) culture flask for culture at 37°C.

[0041] (8) After 3-4 days, gently remove about 1 / 2 of the culture medium in the culture bottle and add fresh DMEM / F12 medium (containing 100 U / mL penicillin and 0.1 mg / mL streptomycin) containing 10% fetal bovine serum. When the cells grow to 80% abundance (about 8 days), subculture and preserve to obtain UC-MSC cells.

[0042] Example 2 Identification of FGF23 as a fibroblast growth factor expressed by MSCs in response to inflammatory stimulation

[0043] (1) In a 6-well cell culture plate filled with DMEM / F12 medium (containing 100 U / mL penicillin and 0.1 mg / mL streptomycin), 2 × 10 5 The UC-MSC cells prepared in Example 1 had a culture medium volume of 2 mL.

[0044] (2) Place a 0.22 μm Transwell co-culture chamber in the well and plate 1×10 5 Inflammatory polarized macrophages were cultured for 24 hours. The inflammatory polarized macrophages were prepared according to the following method: human peripheral blood monocytes were induced to differentiate into mature macrophages by 50 ng / mL M-CSF (solvent: PBS) for 5 days, and then treated with 100 ng / mL LPS (solvent: PBS) for 12 hours to obtain inflammatory polarized macrophages.

[0045] (3) Collecting the UC-MSCs obtained in step (2), and using Q-PCR to analyze the gene expression levels of several fibroblast growth factors, FGF2, FGF4, FGF17, FGF19, FGF21, and FGF23. The results are as follows Figure 1 As shown in the figure, it can be seen that when cultured with inflammatory polarized macrophages, UC-MSC can significantly increase the expression of FGF23, indicating that FGF23 is an FGF expressed by MSC in response to inflammatory stimulation.

[0046] Example 3 FGF23 stimulation and treatment of UC-MSCs and culture of UC-MSCs

[0047] The specific steps of FGF23 stimulation treatment of UC-MSCs and UC-MSC culture are as follows:

[0048] (1) The UC-MSCs prepared in Example 1 were placed in a culture dish or culture bottle and cultured at 37° C. using DMEM / F12 medium containing 10% fetal bovine serum.

[0049] (2) When UC-MSCs grow to about 70-80%, human FGF23 (purchased from GenScript Biotech Z02891) is added to make the FGF23 concentration in the system 500 ng / mL. Calcitriol (added concentration is 5 μM) and saikosaponin A (added concentration is 10 μM) are added simultaneously, and the cells are cultured at 37°C for 48 hours.

[0050] (3) After the culture is completed, add pancreatic enzyme (10 6 The cells were digested by adding 2 mL of 0.25% (g / mL) trypsin at 37°C for 5 min, and UC-MSCs were collected.

[0051] After the stimulated UC-MSCs were co-cultured with inflammatory polarized macrophages (prepared in the same manner as in Example 2), the expression of inflammatory genes in macrophages was detected by qPCR. The results were as follows: Figure 2 As shown, it can be seen that compared with the control group (inflammatory polarized macrophages), this UC-MSC can significantly inhibit the inflammatory polarization of macrophages.

[0052] Example 4 Construction of autoimmune hepatitis animal model

[0053] This example constructs an autoimmune hepatitis mouse model, and the specific steps are as follows:

[0054] (1) On day 0, C57 / BL6J mice (male, 6-8 weeks old) were intraperitoneally injected with a 10% CCl4 solution (solvent: olive oil) at a dose of 10 mL / kg.

[0055] (2) On the first and seventh days, 3×10 9 PFU / animal / time Ad5-CYP2D6 adenovirus, and the autoimmune hepatitis animal model was constructed on day 28. The Ad5-CYP2D6 adenovirus was constructed by transfecting Ad5-CYP2D6 plasmid (purchased from Yunzhou Bio, catalog number: VB900161-4982dpt) into 293A cells, and the transfection used Lipofectamine 2000 transfection reagent and was carried out according to the corresponding instructions.

[0056] Example 5 Preparation of MSC preparation and infusion into animal model

[0057] (1) The UC-MSCs collected in Example 3 were resuspended in physiological saline and washed three times by centrifugation to remove trypsin.

[0058] (2) Resuspend UC-MSCs in sterile saline and use a 100 μm cell sieve to prepare MSCs at a concentration of 10 6 -10 7 cell / mL single cell suspension.

[0059] (3) Human FGF23 is added to the single cell suspension to a final concentration of 1000 ng / mL, and the mixture is mixed evenly to prepare a preparation for intravenous administration.

[0060] (4) Using the autoimmune hepatitis mouse model constructed in Example 4, the mouse was injected with 10 6 The preparation of MSCs with a certain number of cells was infused once every 1 day for one week.

[0061] (5) Efficacy analysis: The mice were killed and serum and liver tissue were collected. The liver tissue was subjected to H&E pathological section analysis. Figure 3 As shown in the figure, it can be seen that the area of ​​liver tissue damage and necrosis in the mouse liver tissue treated with MSC preparations was significantly reduced. The mouse serum was collected and analyzed by a fully automatic biochemical analyzer to obtain the content data of ALT and AST, as shown in the figure. Figure 4 As shown, it can be seen that compared with the autoimmune hepatitis mice (AIH model) not injected with MSC preparations, the injection of MSC preparations can significantly reduce the levels of ALT and AST. The present invention also uses the EILISA kit to detect the levels of inflammatory cytokines and anti-inflammatory factors (IL-10) in serum, the kit item number (IL-1b Lianke Bio EK201B, TNFa Lianke Bio EK282, IL-6 Lianke Bio EK206, IL-10 Lianke Bio EK210). The test results are as follows Figure 5 As shown in the results, it can be seen that the levels of inflammatory cytokines IL-1b, TNFa and IL-6 in the serum of mice treated with MSC preparations decreased significantly, while the level of cytokine IL-10, which promotes inflammation resolution, increased significantly after MSC preparation treatment, indicating that MSC preparations inhibited inflammation in mice and promoted inflammation resolution. The content and phenotype of immune cells in the liver were analyzed by flow cytometry analysis. The results are shown in Figure 6As shown, it can be seen that the content of cytotoxic T cells (CTL, CD8+CD3+) was significantly reduced, and the content of regulatory T cells (Treg, CD4+CD25+) was significantly increased, indicating that the immune inflammatory microenvironment in the liver was improved and the repair process in the liver tissue was enhanced.

[0062] The present invention provides a mesenchymal stem cell preparation and its preparation method and application ideas and methods. There are many methods and ways to implement the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the protection scope of the present invention. All components not specified in this embodiment can be implemented by existing technologies.

Claims

1. A mesenchymal stem cell preparation, characterized in that: Includes human umbilical cord mesenchymal stem cells and fibroblast growth factor 23.

2. The mesenchymal stem cell preparation according to claim 1, characterized in that The fibroblast growth factor 23 is human fibroblast growth factor 23.

3. The mesenchymal stem cell preparation according to claim 1, characterized in that The formulation includes physiological saline.

4. The mesenchymal stem cell preparation according to claim 1, characterized in that In the mesenchymal stem cell preparation, the concentration of human umbilical cord mesenchymal stem cells is 10 6 -10 7 cells / mL, and the concentration of fibroblast growth factor 23 was 100-1000ng / mL.

5. The method for preparing the mesenchymal stem cell preparation according to any one of claims 1 to 4, characterized in that: The steps include: (1) placing human umbilical cord mesenchymal stem cells in a culture medium, culturing until the cell abundance reaches 70%-80%, adding fibroblast growth factor 23, calcitriol and saikosaponin, continuing to culture for 18-48 hours, and adding trypsin for digestion; (2) washing and resuspending the human umbilical cord mesenchymal stem cells obtained by digestion in step (1), and collecting them through a cell sieve to obtain a single cell suspension; (3) Adding fibroblast growth factor 23 to the single cell suspension to obtain a mesenchymal stem cell preparation.

6. The preparation method according to claim 5, characterized in that: In step (1), the human umbilical cord mesenchymal stem cells are extracted according to the following method: adding CDH digestive enzyme to Wharton's jelly for digestion, centrifuging to remove the supernatant, resuspending in DMEM / F12 culture medium containing fetal bovine serum, and culturing until the cell abundance is 70%-80% to obtain human umbilical cord mesenchymal stem cells.

7. The preparation method according to claim 6, characterized in that: The CDH digestive enzyme comprises type II collagenase, neutral protease and hyaluronidase; the CDH digestive enzyme is added in the form of CDH digestive enzyme solution; the solvent of the CDH digestive enzyme solution is DMEM / F12 culture medium, wherein the concentration of type II collagenase is 250U / mL, the concentration of neutral protease is 100U / mL, and the concentration of hyaluronidase is 10U / mL; the volume ratio of the CDH digestive enzyme solution to the Wharton's jelly is 1-5:

1.

8. The preparation method according to claim 5, characterized in that: In step (1), the added concentration of fibroblast growth factor 23 is 100-500 ng / mL; the added concentration of calcitriol is 1-5 μM; and the added concentration of saikosaponin is 1-10 μM.

9. The preparation method according to claim 5, characterized in that: In step (2), physiological saline is used for washing and resuspending; the cell sieve is a 100 μm cell sieve.

10. Use of the mesenchymal stem cell preparation according to any one of claims 1 to 4 in the preparation of a drug for treating autoimmune hepatitis.

Citation Information

Cited By

  • Application of induced pluripotent stem cell-derived mesenchymal stem cells in preparation of medicine for treating acute hepatic failure

    CN121534083A